Meeting
2016 ASCO Annual Meeting
LORELEI: A Phase II randomized, double-blind study of neoadjuvant letrozole plus taselisib (GDC-0032) versus letrozole plus placebo in postmenopausal women with ER-positive/HER2-negative, early-stage breast cancer.
Authors
Cristina Saura
Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain
Cristina Saura , Evandro De Azambuja , Mafalda Oliveira , Peter Christian Dubsky , Dimitrios Zardavas , Christian Fesl , Aditya Bardia , Jesus Soberino , Monica N. Fornier , Katalin Boer , Vivian Ng , Jill O. Fredrickson , Thomas Stout , Stina Singel , Jerry Y. Hsu , Martine J. Piccart-Gebhart , Jose Baselga , Michael Gnant
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—HER2/ER
Track
Breast Cancer
Sub Track
ER+
Clinical Trial Registration Number
NCT02273973
Citation
J Clin Oncol 34, 2016 (suppl; abstr TPS613)
DOI
10.1200/JCO.2016.34.15_suppl.TPS613
Abstract #
TPS613
Poster Bd #
101a
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
![Phase II randomized study of neoadjuvant metformin plus letrozole versus placebo plus letrozole for ER-positive postmenopausal breast cancer [METEOR Study].](https://d201v5jt9ylckg.cloudfront.net/239/13715/176278/176278_poster_pv.jpg)
Phase II randomized study of neoadjuvant metformin plus letrozole versus placebo plus letrozole for ER-positive postmenopausal breast cancer [METEOR Study].
First Author: Jisun Kim
Poster
2019 ASCO Annual Meeting
PIPA: A phase Ib study of β-isoform sparing phosphatidylinositol 3-kinase (PI3K) inhibitor taselisib (T) plus palbociclib (P) and fulvestrant (FUL) in PIK3CA-mutant (mt) ER-positive and taselisib (T) plus palbociclib (P) in PIK3CA-mutant (mt) ER-negative advanced breast cancer.
First Author: Javier Pascual
Poster
2019 ASCO Annual Meeting
Exploratory analysis of the effect of taselisib on downstream pathway modulation and correlation with tumor response in ER-positive/HER2-negative early-stage breast cancer from the LORELEI trial.
First Author: Paolo Nuciforo
Poster
2016 ASCO Annual Meeting
Phase II trial of CC-486, a DNA methyltransferase inhibitor, in combination with fulvestrant in postmenopausal women with ER+, HER2- metastatic breast cancer who have progressed on an aromatase inhibitor (AI).
First Author: Mario Campone